1. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
- Author
-
Instituto de Salud Carlos III, Generalitat de Catalunya, Ministerio de Economía y Competitividad (España), Fundación CRIS contra el Cáncer, China Scholarship Council, European Commission, Casadevall, David, Hernández-Prat, Anna, García-Alonso, Sara, Menendez, Silvia, Qin, Mengjuan, Guardia, Cristina, Morancho, B., Sánchez-Martín, Francisco Javier, Zazo, Sandra, Gavilán, Elena, Sabbaghi, Mohammad A., Eroles, Pilar, Cejalvo, Juan Miguel, Lluch, Ana, Rojo, Federico, Pandiella, Atanasio, Rovira, Ana, Albanell, Joan, Instituto de Salud Carlos III, Generalitat de Catalunya, Ministerio de Economía y Competitividad (España), Fundación CRIS contra el Cáncer, China Scholarship Council, European Commission, Casadevall, David, Hernández-Prat, Anna, García-Alonso, Sara, Menendez, Silvia, Qin, Mengjuan, Guardia, Cristina, Morancho, B., Sánchez-Martín, Francisco Javier, Zazo, Sandra, Gavilán, Elena, Sabbaghi, Mohammad A., Eroles, Pilar, Cejalvo, Juan Miguel, Lluch, Ana, Rojo, Federico, Pandiella, Atanasio, Rovira, Ana, and Albanell, Joan
- Abstract
In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR inhibition and the antibody-drug conjugate (ADC) trastuzumab-emtansine (T-DM1) remains unexplored. We tested T-DM1 plus everolimus in a broad panel of HER2-positive breast cancer cell lines. The combination was superior to T-DM1 alone in four cell lines (HCC1954, SKBR3, EFM192A, and MDA-MB-36) and in two cultures from primary tumor cells derived from HER2-positive patient-derived xenografts (PDX), but not in BT474 cells. In the trastuzumab-resistant HCC1954 cell line, we characterized the effects of the combination using TAK-228 (mTORC1 and -2 inhibitor) and knockdown of the different mTOR complex components. T-DM1 did not affect mTOR downstream signaling nor induct autophagy. Importantly, mTOR inhibition increased intracellular T-DM1levels, leading to increased lysosomal accumulation of the compound. The increased efficacy of mTOR inhibition plus T-DM1 was abrogated by lysosome inhibitors (chloroquine and bafilomycin A1). Our experiments suggest that BT474 are less sensitive to T-DM1 due to lack of optimal lysosomal processing and intrinsic resistance to the DM1 moiety. Finally, we performed several in vivo experiments that corroborated the superior activity of T-DM1 and everolimus in HCC1954 and PDXderived mouse models. In summary, everolimus in combination with T-DM1 showed strong antitumor effects in HER2-positive breast cancer, both in vitro and in vivo. This effect might be related, at least partially, to mTOR-dependent lysosomal processing of T-DM1, a finding that might apply to other ADCs that require lysosomal processing.
- Published
- 2022